MaxCyte Roe from 2010 to 2025

MXCT Stock  USD 3.27  0.08  2.51%   
MaxCyte ROE yearly trend continues to be comparatively stable with very little volatility. ROE is likely to outpace its year average in 2025. From the period from 2010 to 2025, MaxCyte ROE quarterly data regression had r-value of (0.74) and coefficient of variation of  288.99. View All Fundamentals
 
ROE  
First Reported
2010-12-31
Previous Quarter
(0.20)
Current Value
(0.19)
Quarterly Volatility
1.50487895
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5 M, Interest Expense of 138.6 K or Selling General Administrative of 31.2 M, as well as many indicators such as Price To Sales Ratio of 10.73, Dividend Yield of 0.0 or PTB Ratio of 2.22. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
  
Check out the analysis of MaxCyte Correlation against competitors.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

Latest MaxCyte's Roe Growth Pattern

Below is the plot of the Roe of MaxCyte over the last few years. It is MaxCyte's ROE historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
Roe10 Years Trend
Slightly volatile
   Roe   
       Timeline  

MaxCyte Roe Regression Statistics

Arithmetic Mean0.52
Geometric Mean0.53
Coefficient Of Variation288.99
Mean Deviation1.15
Median(0.08)
Standard Deviation1.50
Sample Variance2.26
Range4.3643
R-Value(0.74)
Mean Square Error1.10
R-Squared0.54
Significance0
Slope(0.23)
Total Sum of Squares33.97

MaxCyte Roe History

2025 -0.19
2024 -0.2
2023 -0.16
2022 -0.0779
2021 -0.0766
2020 -0.38
2019 -1.0

About MaxCyte Financial Statements

MaxCyte shareholders use historical fundamental indicators, such as Roe, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
ROE(0.20)(0.19)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.